Deferasirox is under clinical development by Austhera BioSciences and currently in Phase II for Thalassemia. According to GlobalData, Phase II drugs for Thalassemia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Deferasirox’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Deferasirox (DST-0509, KDFX) is under development for the treatment of iron overload in transfusion-dependent major thalassemia (TDT) patients. The drug candidate is formulated as a tablet and administered through oral route. It acts by targeting iron. The drug candidate is developed based on Kinetisol technology.
Austhera BioSciences overview
Austhera BioSciences is a pharmaceutical development company that develops transformative drug candidates and novel chemical entities for the treatment of cancer and rare diseases. Austhera BioSciences is headquartered in Georgetown, Texas, the US.
For a complete picture of Deferasirox’s drug-specific PTSR and LoA scores, buy the report here.